DNA methyltransferase 3b silencing affects locus-specific DNA methylation and inhibits proliferation, migration and invasion in human hepatocellular carcinoma SMMC-7721 and BEL-7402 cells Retraction in /10.3892/ol.2024.14819

Wang,Jia‑Chen; Wang,Zhao; Fan,Yu‑Xia; Si,Ya‑Qing; Wang,Jia-Xiang

doi:10.3892/ol.2015.3077

DNA methyltransferase 3b silencing affects locus-specific DNA methylation and inhibits proliferation, migration and invasion in human hepatocellular carcinoma SMMC-7721 and BEL-7402 cells

Retraction in: /10.3892/ol.2024.14819

Authors:
- Jia‑Chen Wang
- Zhao Wang
- Yu‑Xia Fan
- Ya‑Qing Si
- Jia-Xiang Wang
View Affiliations

Affiliations: Department of Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: March 26, 2015 https://doi.org/10.3892/ol.2015.3077
Pages: 2499-2506
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA methylation is an important regulator of gene transcription, and its role in carcinogenesis has been a topic of considerable interest in previous years. The present study examined the influence of DNA methyltransferase 3b (DNMT3b) on cell proliferation, migration and invasion, and the methylation status of identified tumor suppressor genes in hepatoma SMMC‑7721 and BEL‑7402 cells. DNMT3b was silenced by small interfering RNA (siRNA) in human hepatocellular carcinoma cell lines. Transfection efficiency was verified using a fluorescent imaging system, reverse transcription polymerase chain reaction (RT‑PCR) and western blotting. A cell proliferation assay was performed to evaluate cell viability. Cell cycle distribution and apoptosis were analyzed by flow cytometry. The migratory and invasive ability of cells was measured using a Transwell assay. Methylation‑specific PCR (MSP) was performed to assess methylation in the promoter region of genes. The present data revealed that DNMT3b siRNA successfully inhibited expression of the DNMT3b gene in these two liver cancer cell lines and therefore inhibited the proliferation of the transfected cells, stimulated apoptosis in the cells, led to an accumulation of cells in the G2/M phase and decreased cell migration and invasion. It was also found that silencing DNMT3b expression results in hypomethylation of specific sets of gene promoters and increases the expression of distinct set of genes in HCC cell lines. The present study is therefore useful for assessing the specificity of emerging action based on the altered expression of associated regulatory genes, particularly in methylation-silenced genes.

View Figures

View References

1	Wang Z, Cao Y, Jiang C, Yang G, Wu J and Ding Y: Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: A meta-analysis. PLoS One. 7:e400392012. View Article : Google Scholar : PubMed/NCBI
2	Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, et al: Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 28:3994–4005. 2010. View Article : Google Scholar : PubMed/NCBI
3	Lao Y, Wu H, Zhao C, Wu Q, Qiao F and Fan H: Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma. Biomed Rep. 1:771–775. 2013.PubMed/NCBI
4	Miyake T, Endo K, Honjo S, Hirooka Y and Ikeguchi M: Expression of DNA methyltransferase (DNMT) 1, 3a and 3b proteins in human hepatocellular carcinoma. Yonago Acta Med. 53:1–7. 2010.
5	Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ and Kang GH: Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 163:1371–1378. 2003. View Article : Google Scholar : PubMed/NCBI
6	Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, Gennari L, Tommasini M, Malesci A and Coggi G: Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology. 36:427–432. 2002. View Article : Google Scholar : PubMed/NCBI
7	Yang B, Guo M, Herman JG and Clark DP: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 163:1101–1107. 2003. View Article : Google Scholar : PubMed/NCBI
8	Robertson KD and Wolffe AP: DNA methylation in health and disease. Nat Rev Genet. 1:11–19. 2000. View Article : Google Scholar : PubMed/NCBI
9	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
10	Jones PA: Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet. 13:484–492. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hsieh CL: The de novo methylation activity of Dnmt3a is distinctly different than that of Dnmt1. BMC Biochem. 6:62005. View Article : Google Scholar : PubMed/NCBI
12	Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet. 9:2395–2402. 2000. View Article : Google Scholar : PubMed/NCBI
13	Oh BK, Kim H, Park HJ, Shim YH, Choi J, Park C and Park YN: DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med. 20:65–73. 2007.PubMed/NCBI
14	Baylin S and Bestor TH: Altered methylation patterns in cancer cell genomes: Cause or consequence? Cancer Cell. 1:299–305. 2002. View Article : Google Scholar : PubMed/NCBI
15	Robertson KD: DNA methylation and human disease. Nat Rev Genet. 6:597–610. 2005. View Article : Google Scholar : PubMed/NCBI
16	Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, et al: Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology. 55:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI
17	Lambert MP, Paliwal A, Vaissière T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, et al: Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 54:705–715. 2011. View Article : Google Scholar : PubMed/NCBI
18	Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G and Park YN: Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol. 54:939–947. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hu L, Chen G, Yu H and Qiu X: Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int. 4:423–432. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, et al: Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res. 37:974–983. 2007. View Article : Google Scholar : PubMed/NCBI
21	Yeo W, Wong N, Wong WL, Lai PB, Zhong S and Johnson PJ: High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 25:266–272. 2005. View Article : Google Scholar : PubMed/NCBI
22	Csepregi A, Röcken C, Hoffmann J, Gu P, Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P, et al: APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 134:579–589. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zopf S, Ocker M, Neureiter D, Alinger B, Gahr S, Neurath MF and Di Fazio P: Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer. 12:3862012. View Article : Google Scholar : PubMed/NCBI
24	Steine EJ, Ehrich M, Bell GW, Raj A, Reddy S, van Oudenaarden A, et al: Genes methylated by DNA methyltransferase 3b are similar in mouse intestine and human colon cancer. J Clin Invest. 121:1748–1752. 2011. View Article : Google Scholar : PubMed/NCBI
25	Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 416:552–556. 2002. View Article : Google Scholar : PubMed/NCBI
26	Jin B and Robertson KD: DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 754:3–29. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xu J, Fan H, Zhao ZJ, Zhang JQ and Xie W: Identification of potential genes regulated by DNA methyltransferase 3B in a hepatocellular carcinoma cell line by RNA interference and microarray analysis. Yi Chuan Xue Bao. 32:1115–1127. 2005.PubMed/NCBI
28	Du YF, Liang L, Shi Y, Long QZ, Zeng J, Wang XY and He DL: Multi-target siRNA based on DNMT3A/B homologous conserved region influences cell cycle and apoptosis of human prostate cancer cell line TSU-PR1. Genet Mol Biol. 35:164–171. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kassis ES, Zhao M, Hong JA, Chen GA, Nguyen DM and Schrump DS: Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J Thorac Cardiovasc Surg. 131:298–306. 2006. View Article : Google Scholar : PubMed/NCBI
30	Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H and MacLeod AR: An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem. 277:28176–28181. 2002. View Article : Google Scholar : PubMed/NCBI
31	Yaqinuddin A, Qureshi SA, Qazi R and Abbas F: Down-regulation of DNMT3b in PC3 cells effects locus-specific DNA methylation, and represses cellular growth and migration. Cancer Cell Int. 8:132008. View Article : Google Scholar : PubMed/NCBI
32	Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC and Liaw YF: Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 61:4238–4243. 2001.PubMed/NCBI
33	Teneng I, Tellez CS, Picchi MA, et al: Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer. Oncogene. 34:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
34	Xie F, Ye L, Ta M, Zhang L and Jiang WG: MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. Front Biosci (Schol Ed). 3:621–631. 2011. View Article : Google Scholar : PubMed/NCBI
35	Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu X, Zhao Z, Kong KL, Dong S, Song Y, et al: MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma. Oncogene. 31:2298–2308. 2012. View Article : Google Scholar : PubMed/NCBI
36	Wang J, Li J, Shen J, Wang C, Yang L and Zhang X: MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 12:2272012. View Article : Google Scholar : PubMed/NCBI
37	Wang J, Bhutani M, Pathak AK, Lang W, Ren H, Jelinek J, He R, Shen L, Issa JP and Mao L: Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. Cancer Res. 67:10647–10652. 2007. View Article : Google Scholar : PubMed/NCBI
38	Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrich M, He T, et al: Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev. 21:3110–3122. 2007. View Article : Google Scholar : PubMed/NCBI
39	Sarli L, Bottarelli L, Azzoni C, Campanini N, Di Cola G, Bader G, Iusco D, Salvemini C, Caruso G, Donadei E, et al: Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer. 40:1581–1588. 2004. View Article : Google Scholar : PubMed/NCBI
40	Nelson WG, De Marzo AM and DeWeese TL: The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology. 57:(Suppl 1). 39–45. 2001. View Article : Google Scholar : PubMed/NCBI
41	Wang JX, Zhang YG and Zhao LS: Influence of DNA methyltransferase 3b on FHIT expression and DNA methylation of the FHIT promoter region in hepatoma SMMC-7721 cells. Hepatobiliary Pancreat Dis Int. 8:273–277. 2009.PubMed/NCBI